This study will enroll 176 patients randomized in a 1:1 allocation ratio (88 in each arm) to one of the two arms.~Study arm: SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab~Control arm: SIRT-Y90 + placebos (IV)~The patients will be recruited from up to 13 sites from the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (subjected to feasibility studies and ethics approval). Proposed sites are in Singapore, China, South Korea, and Taiwan.
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90 followed by placebo [control arm] in patients with locally advanced Hepatocellular Carcinoma (HCC).